Here are three things to know:
1. The IMblaze370 phase 3 trial included more than 360 metastatic CRC patients for whom at least two prior chemotherapy regimens had failed.
2. The majority of participants — 90 percent — had tumors characterized by microsatellite stability; tumors with microsatellite instability have been shown to respond to immunotherapy.
3. There was no significant difference in progression-free survival between the treatments.
More articles on gastroenterology:
$5k colonoscopy? Contract dispute in Mississippi could mean patients foot the bill
Pentax Medical posts lecture series on endoscopic infection control — 6 insights
Exact Sciences, Biomerica & more — 4 GI company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
